吉妥單抗
 | |
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目標 | CD33 |
| 臨床資料 | |
| 商品名 | Mylotarg |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618005 |
| 核准狀況 | |
| 懷孕分級 | |
| 给药途径 | 靜脈注射 |
| ATC碼 | |
| 法律規範狀態 | |
| 法律規範 |
|
| 识别信息 | |
| CAS号 | 220578-59-6  |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| 化学信息 | |
| 摩尔质量 | 151500 g·mol−1 |
吉妥單抗（Gemtuzumab ozogamicin，又名：吉妥珠单抗奥佐米星）用於治疗急性骨髓性白血病[7]。特別是針對CD33阳性的患者[7]。与道諾黴素和阿糖胞苷併用[8]。讚静脉緩慢注射給藥[7]。
常见的副作用包括感染和出血[8]。其他副作用包括可能有肝脏问题、 長QT綜合症、不孕和腫瘤溶解症候群[8] [9]。孕期使用可能對婴儿有害[9]。它是一种与细胞毒素结合的单克隆抗生素也就是抗體-藥物複合體[8]。抗体會与 CD33 结合，細胞毒性为卡奇霉素[8]。
吉妥單抗于 2017 年及2018年在美国及歐洲取得医疗使用許可[9] [8]。
参考文獻
[编辑]- ^ 1.0 1.1 Mylotarg Australian prescription medicine decision summary. Therapeutic Goods Administration (TGA). 17 April 2020 [17 August 2020].
- ^ AusPAR: Gemtuzumab ozogamicin. Therapeutic Goods Administration (TGA) (报告). October 2020.
- ^ Summary Basis of Decision (SBD) for Mylotarg. Health Canada. 23 October 2014 [29 May 2022].
- ^ Mylotarg 5mg powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC). (emc). 29 October 2019 [17 August 2020].
- ^ Mylotarg- gemtuzumab ozogamicin injection, powder, lyophilized, for solution. DailyMed. 29 June 2020 [17 August 2020].
- ^ Mylotarg EPAR. European Medicines Agency (EMA). 17 September 2018 [28 February 2020].
- ^ 7.0 7.1 7.2 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021: 916. ISBN 978-0857114105.
- ^ 8.0 8.1 8.2 8.3 8.4 8.5 Mylotarg. [3 December 2021]. （原始内容存档于2 June 2020）.
- ^ 9.0 9.1 9.2 Gemtuzumab Monograph for Professionals. Drugs.com. [3 December 2021]. （原始内容存档于23 January 2021） （英语）.
外部連結
[编辑]- Clinical trial number NCT00372593 for "Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia" at ClinicalTrials.gov
